Skip to content
Biotechnology, Business Company News

ASX Hopeful Aegros Appoints Ex-MP As Advisory Committee Chair

Aegros 3 mins read

Australia’s leading blood fractionator announces a trio of strategic advisor appointments as it lays the

groundwork for an IPO 


  • Aegros has established a Strategic Advisory Committee (SAC), to provide advice to the Board in preparation for the company’s Initial Public Offering (IPO).
  • The high-profile SAC members will be drawn from experts in their fields, to provide the Board with strategic advice in the lead up to its IPO.
  • This comes after the company signed an agreement with the Queensland Government to build a 1,000,000 litre facility in Springfield, southwest of Brisbane worth over $350 million.

23 November:

AEGROS today cemented itself as the leading new technology blood fractionator in Australia by announcing a number of key advisory appointments that will help guide the company towards an Initial Public Offering during 2024.

Initial appointees to the Strategic Advisory Committee bring the following expertise and profile to the company:

  • Mr Dave Sharma – Committee Chairman. Dave was the Australian Ambassador to Israel before being elected as the Federal Member for Wentworth. Dave will provide expert advice in the area of Government relations and offshore business development.
  • Mr Jan Bult - Jan established and was the President of the Plasma Protein Therapeutics Association (PPTA) for 23 years. Jan will provide advice on the therapeutic plasma industry.
  • Dr Erin Evans is the CEO of Life Sciences Queensland – the peak life sciences body in Queensland. Erin will provide advice on engagement with the Queensland Government, and the life sciences research and corporate community.

The move to establish its Strategic Advisory Committee follows the Board’s announcement in August that it had appointed Ernst & Young as company auditors, another cornerstone appointment in the preparation for an IPO. 

“With the completion of our Covid-19 hyperimmune clinical trial and associated impending product registration on the Australian Register of Therapeutic Goods, we feel now is the right time to add the specific subject matter expertise to maximise the value of a public listing for our shareholders,” added Professor Hari Nair, Co-founder of Aegros.

With his experience and high profile as a former Australian Ambassador and Member of Federal Parliament, Dave Sharma said: “There are few Australian private companies with as much to offer investors, governments, the medical community, and patients, as Aegros. It is an honour to be asked to join this committee and to help guide one of Australia’s greatest potential companies.”




With deep plasma sector experience, Jan Bult also reflected on joining Aegros as a Strategic Advisor, stating he is “extremely pleased to be asked to join Aegros’ Strategic Advisory Committee and to bring my decades of experience to the challenge of making enough plasma derived medicinal products (PDMPs) for the world. The plasma medicine sector has been waiting for a company like Aegros to come along and change the dynamics of what is possible, and I greatly look forward to contributing to that effort.”

Entrepreneur and business leader, Erin Evans said today it was “an exciting time to join Aegros, a company that has the vision, the innovation, and the capacity to disrupt a plasma market controlled by a few international companies. Aegros provides a pathway to solving the supply issues that bedevil patient advocates, doctors, and government health decision makers alike. I look forward to working with Aegros on the company’s road map to an IPO.”

Co-founder of Aegros, Mr John Manusu said ”Aegros’ immediate future is exciting having  successfully concluded our clinical trial and the pending registration of our first product. With these goals in sight, it is appropriate to start planning for our IPO in late 2024,”

About us:


Aegros is an Australian technology leader in the US$28B global therapeutic plasma market. Its GMP licensed HaemaFrac® lifts process yields to over 85%, reducing cost and carbon emissions while enhancing product safety. The Company expects the clinical trials of its first product, a Covid-19 hyperimmune, to be completed shortly.

Aegros is designing, constructing, validating and operating a 1 million litre HaemaFrac® facility with support from the Queensland Government which is expected to come online in 2026. This HaemaFrac® facility will produce Albumin, IVIG and other plasma products for the Australian and overseas markets.

Contact details:

·         Tim Cook, The Civic Partnership: +61 428 862 436


Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.